Development of a novel frailty index to predict mortality in patients with end‐stage liver disease

Jennifer C. Lai, Kenneth E. Covinsky, Jennifer L. Dodge, W. John Boscardin, Dorry L. Segev, John P. Roberts, Sandy Feng – 19 April 2017 – Cirrhosis is characterized by muscle wasting, malnutrition, and functional decline that confer excess mortality not well quantified by the Model for End‐Stage Liver Disease (MELD) Sodium (MELDNa) score. We aimed to develop a frailty index to capture these extrahepatic complications of cirrhosis and enhance mortality prediction in patients with cirrhosis.

Up‐regulation of golgi α‐mannosidase IA and down‐regulation of golgi α‐mannosidase IC activates unfolded protein response during hepatocarcinogenesis

Hsiao‐Chen Tu, Yung‐Chun Hsiao, Wan‐Yu Yang, Shin‐Lin Tsai, Hua‐Kuo Lin, Chong‐Yi Liao, Jeng‐Wei Lu, Yu‐Ting Chou, Horng‐Dar Wang, Chiou‐Hwa Yuh – 19 April 2017 – α‐1,2 mannosidases, key enzymes in N‐glycosylation, are required for the formation of mature glycoproteins in eukaryotes. Aberrant regulation of α‐1,2 mannosidases can result in cancer, although the underlying mechanisms are unclear. Here, we report the distinct roles of α‐1,2 mannosidase subtypes (MAN1A, MAN1B, ERMAN1, MAN1C) in the formation of hepatocellular carcinoma (HCC).

Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C–positive recipients

Silvia Martini, Francesco Tandoi, Lodovico Terzi di Bergamo, Silvia Strona, Bruna Lavezzo, Marco Sacco, Francesca Maione, Federica Gonella, Paolo Strignano, Dominic Dell Olio, Mauro Salizzoni, Giorgio Maria Saracco, Renato Romagnoli – 19 April 2017 – Although early allograft dysfunction (EAD) negatively impacts survival from the first months following liver transplantation (LT), direct‐acting antiviral agents (DAAs) have revolutionized hepatitis C virus (HCV) therapy.

Adult‐onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity

Christopher Koh, Sasan Sakiani, Pallavi Surana, Xiongce Zhao, Jason Eccleston, David E. Kleiner, David Herion, T. Jake Liang, Jay H. Hoofnagle, Milica Chernick, Theo Heller – 19 April 2017 – Cystic fibrosis (CF) liver disease (CFLD), a leading cause of death in CF, is mostly described in pediatric populations. Adult‐onset CFLD lacks sufficient characterization and diagnostic tools. A cohort of CF patients without CFLD during childhood were followed for up to 38 years with serologic testing, imaging, and noninvasive fibrosis markers.

Hepatic artery reconstruction in living donor liver transplantation using surgical loupes: Achieving low rate of hepatic arterial thrombosis in 741 consecutive recipients—tips and tricks to overcome the poor hepatic arterial flow

Ping‐Chun Li, Ashok Thorat, Long‐Bin Jeng, Horng‐Ren Yang, Ming‐Li Li, Chun‐Chieh Yeh, Te‐Hung Chen, Shih‐Chao Hsu, Kin‐Shing Poon – 19 April 2017 – The reconstruction of the hepatic artery (HA) is the most complex step in living donor liver transplantation (LDLT) because of the smaller diameter of the artery and the increased risk of HA‐related complications. Because of the smaller diameter of the HA, many centers use a microsurgical technique with interrupted sutures for arterial anastomosis.

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction

Paula Cox‐North, Kelsey L. Hawkins, Sean T. Rossiter, Marie N. Hawley, Renuka Bhattacharya, Charles S. Landis – 18 April 2017 – Sofosbuvir (SOF) is a nonstructural 5B polymerase inhibitor with activity in all hepatitis C virus (HCV) genotypes and is the backbone of many anti‐HCV drug regimens. SOF is converted into inactive metabolites that undergo renal excretion.

Subscribe to